Computational Design of Broadly Neutralizing Antibodies for Influenza A Virus: A Structural Virology Approach

Introduction

Influenza A virus (IAV) remains a persistent threat to both animal and public health, causing recurring outbreaks in poultry, swine, horses, and other mammalian hosts. The continuous antigenic drift and shift of the hemagglutinin (HA) glycoprotein necessitate annual vaccine updates and limit the efficacy of existing antiviral strategies [1, 2]. Broadly neutralizing antibodies (bnAbs) that target conserved epitopes on HA offer a promising alternative for therapeutic and prophylactic intervention across multiple IAV subtypes [3, 4]. Computational structural virology has emerged as a powerful paradigm for the rational design and optimization of such bnAbs, enabling high-throughput in silico screening and atomic-level characterization of antibody-antigen interfaces [5, 6]. This article provides a comprehensive review of computational methods for designing bnAbs against IAV, focusing on the structural properties of HA, molecular docking and molecular dynamics (MD) simulations, the application of Rosetta and AlphaFold for design and optimization, and in silico screening for cross-reactive breadth. Case studies of prototypical bnAbs such as CR6261 and F10 are discussed to illustrate the translational potential of these approaches.

Structure of Hemagglutinin and Its Conserved Epitopes

The HA trimer is composed of a globular head domain (HA1) and a membrane-proximal stem domain (HA2). The head domain contains the receptor-binding site (RBS) and is highly variable, whereas the stem domain is more conserved across IAV subtypes and mediates pH-dependent membrane fusion [2, 7]. Most bnAbs identified to date target the HA stem, specifically the fusion peptide region and the hydrophobic groove near the base of the trimer [8, 9, 10]. Structural studies have defined at least four major conserved epitope classes: (i) the stem helix A region, (ii) the fusion peptide and its surrounding pocket, (iii) the trimer interface, and (iv) the lateral face of the stem [11, 12, 13]. Antibodies that bind these epitopes can neutralize multiple group 1 and/or group 2 subtypes, and in some cases both [14, 15, 4].

Key structural determinants of breadth include the length and conformation of the antibody heavy chain complementarity-determining region 3 (CDR H3). For example, germline gene IGHV1-69 is frequently used by stem-directed bnAbs, and polymorphisms in this gene can influence the breadth of the antibody repertoire [11, 16, 17]. The binding interface often involves main chain contacts with HA stem residues that are less prone to mutation, providing a structural basis for cross-reactivity [9, 18]. Cryo-electron microscopy and X-ray crystallography of HA-bnAb complexes, such as those represented by PDB IDs 3GBM and 3FKU, have revealed critical paratope-epitope contacts [4, 7]. Interactive visualization of these structures using a 3D protein viewer can aid in understanding the steric and electrostatic complementarity required for broad neutralization.

Computational Docking and Molecular Dynamics Simulations

Molecular docking is a core computational tool used to predict the binding pose of an antibody fragment (Fab) or single-chain variable fragment (scFv) onto HA [5, 19, 20]. Software packages such as AutoDock, RosettaDock, and HADDOCK rank candidate complexes based on scoring functions that account for van der Waals forces, electrostatics, desolvation, and hydrogen bonding [19]. Docking simulations are often performed using HA structures derived from X-ray crystallography or cryo-EM; when experimental structures are unavailable, homology models can be built from related subtypes [21].

Molecular dynamics (MD) simulations with packages such as GROMACS allow for the evaluation of complex stability and the identification of key energetic hotspots [5, 6]. MD trajectories (typically 100-500 ns) can be analyzed using MM/GBSA or MM/PBSA methods to estimate binding free energies and decompose per-residue contributions [5, 6]. These calculations are essential for distinguishing true binding events from docking artifacts and for guiding subsequent affinity maturation. For example, computational alanine scanning can pinpoint residues in the antibody CDRs whose mutation improves binding affinity or breadth [6, 20].

In the context of IAV, docking and MD have been used to characterize the interaction of bnAbs with both group 1 (e.g., H1, H5, H9) and group 2 (e.g., H3, H7) HA subtypes [14, 15, 22]. The stem epitope is often partially occluded by glycans in certain subtypes, and MD simulations can reveal dynamic glycan movements that modulate accessibility [7]. Furthermore, targeted MD simulations of the pH-induced conformational change in HA can predict how antibodies might block the fusogenic transition [9, 10].

Rosetta and AlphaFold for Antibody Design and Optimization

The Rosetta software suite provides a versatile framework for computational antibody design and optimization [5, 6, 4]. RosettaAntibody and RosettaAntibodyDesign enable the in silico grafting of CDR loops onto a human or animal antibody framework, followed by iterative sequence optimization to improve binding affinity and cross-reactivity [5, 6]. The multistate design protocol in Rosetta allows simultaneous optimization against multiple HA subtypes, thereby ensuring breadth [6]. This approach was successfully employed to improve the affinity of a stem-binding antibody against seasonal H1 strains, demonstrating compensatory mutations in CDR H2 and CDR H3 that enhanced contacts with conserved stem residues [6].

AlphaFold, particularly AlphaFold2 and its multimer mode, has revolutionized the prediction of protein-protein complex structures [23, 5]. When combined with structure prediction servers, AlphaFold can generate high-confidence models of HA-bnAb complexes without prior experimental structures, accelerating the design cycle [23, 5]. For instance, computational designs incorporating AlphaFold-predicted interfaces have been used to generate HA stem-binding proteins that confer in vivo protection in animal models [20]. Moreover, integrative workflows that combine AlphaFold predictions with Rosetta refinement have been shown to yield designs with experimentally validated neutralization activity [23, 5].

Beyond structure prediction, deep learning tools for protein binder design (e.g., RFdiffusion, ProteinMPNN, BindCraft) are now being applied to bnAb engineering. These methods can generate de novo antibody-like scaffolds that target conserved HA epitopes, offering an alternative to classical CDR grafting [20]. The integration of such AI-driven design with molecular dynamics validation represents the current frontier in computational antibody design.

In Silico Screening for Cross-Reactivity Across Subtypes

A critical goal in bnAb design is achieving breadth across the extensive antigenic diversity of IAV. Computational screening methods assess cross-reactivity by docking or superimposing a designed antibody model against a panel of HA structures representing multiple subtypes and clades [14, 24, 25, 26]. The computationally optimized broadly reactive antigen (COBRA) methodology uses a sequence- and structure-based approach to design immunogens that elicit broad antibody responses; a similar principle can be applied to the design of the antibody itself [24, 25, 26].

Structure-based virtual screening of small molecule or peptide libraries against the conserved HA stem pocket has identified leads that functionally mimic bnAbs [14, 27, 21, 22]. Such peptidic or small-molecule inhibitors can serve as candidate therapeutics, and computational docking can also identify antibody paratopes that recapitulate these key interactions [14, 21, 22]. For bnAbs that recognize the neuraminidase (NA) active site, computational screening against a panel of NA subtypes has revealed a recurring CDR H3 motif [28].

Epitope prediction algorithms, such as those trained on known bnAb-HA cocrystal structures, can scan the HA stem for novel conserved patches [13]. These predictions can then be validated through molecular docking against a diverse HA library. The Immune Epitope Database (IEDB) provides a rich resource for known B-cell epitopes and can be queried to prioritize target regions [13]. Ultimately, a combination of docking scores (e.g., binding energy, shape complementarity) and phylogenetic breadth (e.g., number of subtypes predicted to bind) guides the selection of lead candidates for experimental testing.

Case Studies: CR6261 and F10

CR6261 and F10 are two prototypical bnAbs that have been extensively characterized structurally and functionally. CR6261 targets the stem region of group 1 HA subtypes, using a long CDR H3 that inserts into a hydrophobic crevice near the fusion peptide [4, 7]. Computational modeling of CR6261-HA complexes (PDB 3GBM) revealed that the antibody binding prevents the low-pH-induced conformational rearrangement required for membrane fusion [4, 7]. Subsequent computational optimization of CR6261-like antibodies using Rosetta yielded variants with improved affinity and expanded breadth to include group 2 subtypes [6, 4].

F10 was isolated from a human phage display library and shown to neutralize diverse H5N1 strains by binding to a conserved epitope in the HA stem [18]. Structural analysis of F10 in complex with H5 HA (PDB 3FKU) highlighted the importance of framework residues in supporting the CDR H3 loop [18]. In silico alanine scanning and docking against other avian and swine HA subtypes confirmed that F10 could cross-react with several group 1 strains [18]. More recently, computational design approaches have been used to generate multidomain antibodies that combine the breadth of CR6261 and F10 into a single molecule [4].

The following workflow diagram summarizes the key computational steps discussed in this review.

graph TD
    A[IAV HA Sequence/Structure Data], > B[Identification of Conserved Epitopes]
    B, > C[Computational Docking of Antibody Leads]
    C, > D[MD Simulation & Free Energy Analysis]
    D, > E[In Silico Cross-Reactivity Screening]
    E, > F{Lead Selection}
    F, > G[Rosetta/AlphaFold Optimization]
    G, > H[Experimental Validation]
    H, > I{In Vivo Efficacy?}
    I, > J[Preclinical Development]
    I, > C

The pipeline integrates structure prediction, docking, dynamics, and optimization to iteratively improve bnAb candidates.

Conclusion

Computational structural virology provides a powerful toolkit for the design of broadly neutralizing antibodies against influenza A virus. By exploiting the conserved architecture of the HA stem and leveraging high-resolution structural data, in silico methods can rapidly generate, screen, and optimize antibody candidates with broad cross-reactivity. Molecular docking and MD simulations enable detailed biophysical characterization of antibody-antigen interfaces, while Rosetta and AlphaFold facilitate sequence-level optimization and de novo design. The successful application of these methods to bnAbs such as CR6261 and F10 underscores their translational potential for veterinary medicine, where IAV continues to cause significant morbidity and economic losses in poultry, swine, and equine populations. Future developments in AI-driven protein engineering and multistate design will further enhance the ability to create universal antibody therapeutics for influenza A.

References

[1] Zost SJ, Wu NC, Hensley SE et al. Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens. J Infect Dis. 2019. PMID: 30535315.

[2] Wu NC, Wilson IA. A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus. J Mol Biol. 2017. PMID: 28648617.

[3] Mahrous NN, Alhumaidan OS, Alkhoshaiban AS et al. Broadly neutralizing monoclonal antibodies against influenza A viruses: current insights and future directions. Front Microbiol. 2025. PMID: 41602762.

[4] Laursen NS, Friesen RHE, Zhu X et al. Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. Science. 2018. PMID: 30385580.

[5] Duan H, Chi X, Yang X et al. Computational design and improvement of a broad influenza virus HA stem targeting antibody. Structure. 2025. PMID: 39884272.

[6] Sevy AM, Wu NC, Gilchuk IM et al. Multistate design of influenza antibodies improves affinity and breadth against seasonal viruses. Proc Natl Acad Sci U S A. 2019. PMID: 30642961.

[7] Harris AK, Meyerson JR, Matsuoka Y et al. Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. Proc Natl Acad Sci U S A. 2013. PMID: 23460696. *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[8] Zost SJ, Dong J, Gilchuk IM et al. Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface. J Clin Invest. 2021. PMID: 34156974.

[9] Gong X, Yin H, Shi Y et al. Conserved stem fragment from H3 influenza hemagglutinin elicits cross-clade neutralizing antibodies through stalk-targeted blocking of conformational change during membrane fusion. Immunol Lett. 2016. PMID: 26875772.

[10] Tan GS, Lee PS, Hoffman RM et al. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol. 2014. PMID: 25210195.

[11] Fischer AA, Corcoran M, Brouwer PJM et al. Genetically diverse influenza antibodies highlight the role of IG germline gene variation and inform population-comprehensive vaccine strategies. Immunity. 2026. PMID: 41895293.

[12] Bangaru S, Zhang H, Gilchuk IM et al. A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Nat Commun. 2018. PMID: 29991715.

[13] Ren J, Ellis J, Li J. Influenza A HA's conserved epitopes and broadly neutralizing antibodies: a prediction method. J Bioinform Comput Biol. 2014. PMID: 25208658.

[14] Kadam RU, Juraszek J, Brandenburg B et al. Small molecule-constrained paratope mimetic bicyclic peptides as potent inhibitors of group 1 and 2 influenza A virus hemagglutinins. Proc Natl Acad Sci U S A. 2026. PMID: 41875158.

[15] Gilchuk IM, Dong J, Irving RP et al. Pan-H7 influenza human antibody virus neutralization depends on avidity and steric hindrance. JCI Insight. 2025. PMID: 40471690.

[16] Fischer AA, Corcoran M, Brouwer PJM et al. Isolation of genetically diverse influenza antibodies highlights the role of IG germline gene variation and informs the design of population-comprehensive vaccine strategies. bioRxiv. 2025. PMID: 40747420.

[17] Avnir Y, Watson CT, Glanville J et al. IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity. Sci Rep. 2016. PMID: 26880249.

[18] Zhu X, Guo YH, Jiang T et al. A unique and conserved neutralization epitope in H5N1 influenza viruses identified by an antibody against the A/Goose/Guangdong/1/96 hemagglutinin. J Virol. 2013. PMID: 24049169.

[19] Mathew S, Al Thani AA, Yassine HM. Computational screening of known broad-spectrum antiviral small organic molecules for potential influenza HA stem inhibitors. PLoS One. 2018. PMID: 30180218.

[20] Koday MT, Nelson J, Chevalier A et al. A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response. PLoS Pathog. 2016. PMID: 26845438.

[21] Kadam RU, Wilson IA. A small-molecule fragment that emulates binding of receptor and broadly neutralizing antibodies to influenza A hemagglutinin. Proc Natl Acad Sci U S A. 2018. PMID: 29610325.

[22] Kadam RU, Juraszek J, Brandenburg B et al. Potent peptidic fusion inhibitors of influenza virus. Science. 2017. PMID: 28971971.

[23] Huang CQ, Hills RA, Carnell GW et al. Computationally designed haemagglutinin with nanocage plug-and-display elicits pan-H5 influenza vaccine responses. Emerg Microbes Infect. 2025. PMID: 40476519.

[24] Reneer ZB, Jamieson PJ, Skarlupka AL et al. Computationally Optimized Broadly Reactive H2 HA Influenza Vaccines Elicited Broadly Cross-Reactive Antibodies and Protected Mice from Viral Challenges. J Virol. 2020. PMID: 33115871.

[25] Sautto GA, Kirchenbaum GA, Abreu RB et al. A Computationally Optimized Broadly Reactive Antigen Subtype-Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against Hemagglutinin. J Immunol. 2020. PMID: 31811019.

[26] Nuñez IA, Ross TM. Human COBRA 2 vaccine contains two major epitopes that are responsible for eliciting neutralizing antibody responses against heterologous clades of viruses. Vaccine. 2020. PMID: 31733946.

[27] Yao Y, Kadam RU, Lee CD et al. An influenza A hemagglutinin small-molecule fusion inhibitor identified by a new high-throughput fluorescence polarization screen. Proc Natl Acad Sci U S A. 2020. PMID: 32690700.

[28] Jo G, Yamayoshi S, Ma KM et al. Structural basis of broad protection against influenza virus by human antibodies targeting the neuraminidase active site via a recurring motif in CDR H3. Nat Commun. 2025. PMID: 40750588.

[29] Deng Y, Tang M, Ross TM et al. Repeated vaccination with homologous influenza hemagglutinin broadens human antibody responses to unmatched flu viruses. Elife. 2025. PMID: 41231113.

[30] Amitai A, Sangesland M, Barnes RM et al. Defining and Manipulating B Cell Immunodominance Hierarchies to Elicit Broadly Neutralizing Antibody Responses against Influenza Virus. Cell Syst. 2020. PMID: 33031741.

[31] Wu NC, Yamayoshi S, Ito M et al. Recurring and Adaptable Binding Motifs in Broadly Neutralizing Antibodies to Influenza Virus Are Encoded on the D3-9 Segment of the Ig Gene. Cell Host Microbe. 2018. PMID: 30308159.

[32] Honda-Okubo Y, Rajapaksha H, Sajkov D et al. Panblok-H1+advax H1N1/2009pdm vaccine: Insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine. Hum Vaccin Immunother. 2017. PMID: 28301280.

[33] Impagliazzo A, Milder F, Kuipers H et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science. 2015. PMID: 26303961.